Rebamipide (OPC-12759) in the Treatment of Dry Eye: A Randomized, Double-Masked, Multicenter, Placebo-Controlled Phase II Study.
To investigate the dose response for efficacy of 1% and 2% rebamipide ophthalmic suspension compared with placebo in patients with dry eye.
A randomized, double-masked, multicenter, placebo-controlled, parallel-group, dose-response phase II study.
A total of 308 patients with dry eye.
Pardon me for not getting excited yet (we've been here before with this drug... long time ago now) but Rebamipide is back in Phase III clinicals. At this point though - rather like Diquafosol - it's already approved on being marketed in Japan. It will be interesting to see whether it makes it through the FDA this time around.
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
Regenerx has reported positive results from their recent Phase II clinical trial. Sounds promising. Wish it were a larger cohort though.
RGN-259 Significantly Improves Signs and Symptoms of Severe Dry Eye in Phase 2 Clinical Trial
June 20, 2012
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is reporting preliminary results from a double-masked, vehicle-controlled, physician-sponsored
Rebamipide Increases the Mucin-Like Glycoprotein Production in Corneal Epithelial Cells.
J Ocul Pharmacol Ther. 2012 Feb 15.
Dry eye is a multifactorial disease of tears and the ocular surface due to tear deficiency or excessive tear evaporation. Tear film instability is due to a disturbance in ocular surface mucin leading to a dysfunction of mucin, resulting in dry eye. In this study, we examined the effect of rebamipide, an anti-ulcer agent, on
Not too much to write home about here.
A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye.
Semba CP, Torkildsen GL, Lonsdale JD, McLaurin EB, Geffin JA, Mundorf TK, Kennedy KS, Am J
To investigate the efficacy and safety of an investigational integrin antagonist (SAR 1118) ophthalmic solution compared to placebo (vehicle) in subjects with dry eye disease.